05638nam 2201561z- 450 991057687280332120220621(CKB)5720000000008448(oapen)https://directory.doabooks.org/handle/20.500.12854/84579(oapen)doab84579(EXLCZ)99572000000000844820202206d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierUrological Cancer 2021MDPI - Multidisciplinary Digital Publishing Institute20221 online resource (328 p.)3-0365-3048-7 3-0365-3049-5 Cancer of the urological sphere is a disease continuously increasing in numbers in the statistics of tumor malignancies in Western countries. Although this fact is mainly due to the contemporary increase of life expectancy of the people in these geographic areas, many other factors do contribute as well to this growth. Urological cancer is a complex and varied disease of different organs and mainly affects the male population. In fact, kidney, prostate, and bladder cancer are regularly included in the top-ten list of the most frequent neoplasms in males in most statistics. The female population, however, has also increasingly found itself affected by renal and bladder cancer in the last decade. Considering these altogether, urological cancer is a problem of major concern in developed societies. This Topic Issue of Cancers intends to shed some light into the complexity of this field and will consider all useful and appropriate contributions that scientists and clinicians may provide to improve urological cancer knowledge for patients' benefit. The precise identification of the molecular routes involved, the diagnostic pathological criteria in the grey zones, the dilemma of T1G3 management, and the possible treatment options between superficial, nonmuscle-invasive and muscle-invasive diseases will be particularly welcomed in this Issue.ChemistrybicsscResearch & information: generalbicssc177Lu-PSMAabirateroneablation marginsadvanced urothelial carcinomaAHNAK2autopsyBacillus Calmette-Guérin (BCG)biomarkerbiomarkersbiopsybladder cancerbladder cancer cell linesbladder carcinomacancercell migrationcomparative effectivenesscomparative oncologyctDNAdecision makingdiagnosisdivergent differentiationdocetaxeldogenzalutamideepiplakinepithelial-mesenchymal transitionfluorescence confocal microscopyfocal therapyfrail patientsfrailtyFTY-720game theorygenomic analysisgenomic signaturesglutaminaseHounsfield unitsimage-guidedimmune checkpoint inhibitorimmune checkpoint inhibitorsimmunohistochemistryimmunotherapyin situ methodsinflammationinflammatory indiceslatent cancerliquid biopsymachine learningmagnetic resonance imagingmCRPCmetastasectomymetastasismetastatic prostate cancermicroenvironmentmolecular subtypesmortalityn/anovel hormonal therapiesOIP5oncological outcomespapillary renal cell carcinomaPD-1PD-L1PLK1positron-emission tomographypostoperative complicationspreclinical studiesprediction modelpreneoplastic lesionprognosisprognosticprognostic factorprognostic indexprostateprostate biopsyprostate cancerprostatic atrophyprostatic neoplasmsPSAPSMA-RLTpsoas muscleradical cystectomyradiosensitisationradiotherapyreal-world treatment patternrenal cell carcinomascreening trialsphingosine 1-phosphate receptor 1stereotactic body radiotherapysurvivaltherapyTRIPODtumor ecologytumor thrombustumorigenesistumour mutational boardultrasonographyurinary bladder neoplasmsurineurothelial carcinomavariant morphologyChemistryResearch & information: generalManini ClaudiaLópez José I.BOOK9910576872803321Urological Cancer 20213034948UNINA